This page shows the latest siltuximab news and features for those working in and with pharma, biotech and healthcare.
Sylvant (siltuximab) offers a more promising alternative, however, and has demonstrated in clinical trials it can reduce the size of tumours and stabilise disease symptoms, such as fever. ... Not every MCD patient will be eligible for treatment with
Sylvant (siltuximab), marketed by Johnson &Johnson subsidiary Janssen Biotech, is the first drug backed by the FDA to treat multicentric Castleman's disease, which the agency describes as a rare disorder
Johnson &Johnson (J&J) has filed for approval of its investigational drug siltuximab in both the EU and US as a treatment for a rare blood disorder. ... The submissions are based primarily on data from the randomised MCD2001 study, which compared
Also on the list are fulranumab for osteoarthritis pain; siltuximab for castleman's disease, a rare disorder that is similar to lymphoma; TMC-207 for MDR tuberculosis; TMC 435 for hepatitis
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...